Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study.

Liver Cancer · 2025 · PMC12097796 · PMID 40417458

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

3 h, i): In both the lenvatinib and bevacizumab groups, diabetic patients showed a trend toward better OS compared to nondiabetic patients, though this was not statistically significant ( p = 0.062, Fig. 3 h).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.